MedTrace Logo

A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

NCT01156571 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 11145

Last updated 2014-02-04

Study results available
· View outcomes & findings →

Summary

The study is designed to compare the efficacy and safety profile of cangrelor to standard of care in patients require percutaneous coronary intervention (PCI).

Conditions

  • Atherosclerosis
  • Percutaneous Coronary Intervention
  • Acute Coronary Syndrome

Interventions

DRUG

cangrelor P2Y12 (platelet) inhibitor

DRUG

Clopidogrel - 300 or 600 mg (study arm)

Over encapsulated tablets.

DRUG

Clopidogrel 600 mg post cangrelor

over-encapsulated clopidogrel (600 mg)

Sponsors & Collaborators

  • The Medicines Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01156571 on ClinicalTrials.gov